| Osteoarthritis prevalence and modifiable factors: a population study R Plotnikoff, N Karunamuni, E Lytvyak, C Penfold, D Schopflocher, ... BMC public health 15, 1-10, 2015 | 247 | 2015 |
| Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome C Efe, AV Kulkarni, BT Beretta‐Piccoli, B Magro, A Stättermayer, ... Hepatology 76 (6), 1576-1586, 2022 | 79 | 2022 |
| Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis M Ebadi, RA Bhanji, VC Mazurak, E Lytvyak, A Mason, AJ Czaja, ... Alimentary pharmacology & therapeutics 49 (2), 173-182, 2019 | 73 | 2019 |
| Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome C Efe, M Torgutalp, I Henriksson, F Alalkim, E Lytvyak, H Trivedi, F Eren, ... Journal of gastroenterology and hepatology 36 (4), 936-942, 2021 | 50 | 2021 |
| Validation of risk scoring systems in ursodeoxycholic acid–treated patients with primary biliary cholangitis C Efe, K Tascilar, I Henriksson, E Lytvyak, F Alalkim, H Trivedi, F Eren, ... Official journal of the American College of Gastroenterology| ACG 114 (7 …, 2019 | 48 | 2019 |
| Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis C Corpechot, F Carrat, F Gaouar, F Chau, G Hirschfield, A Gulamhusein, ... Journal of hepatology 77 (6), 1545-1553, 2022 | 44 | 2022 |
| Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS) HH Nguyen, AA Shaheen, N Baeza, E Lytvyak, SJ Urbanski, AL Mason, ... PloS one 13 (3), e0193960, 2018 | 41 | 2018 |
| Selection of quality indicators in IBD: integrating physician and patient perspectives A Bitton, M Vutcovici, E Lytvyak, N Kachan, B Bressler, J Jones, ... Inflammatory Bowel Diseases 25 (2), 403-409, 2019 | 34 | 2019 |
| Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis C Efe, C Lammert, K Taşçılar, R Dhanasekaran, B Ebik, ... Liver international 42 (3), 607-614, 2022 | 31 | 2022 |
| Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis CRH Hedin, G Sado, N Ndegwa, E Lytvyak, A Mason, A Montano-Loza, ... Clinical Gastroenterology and Hepatology 18 (10), 2295-2304. e2, 2020 | 27 | 2020 |
| Combination antiretroviral studies for patients with primary biliary cirrhosis E Lytvyak, AJ Montano-Loza, AL Mason World journal of gastroenterology 22 (1), 349, 2016 | 26 | 2016 |
| Trends in obesity across Canada from 2005 to 2018: a consecutive cross-sectional population-based study E Lytvyak, S Straube, R Modi, KK Lee Canadian Medical Association Open Access Journal 10 (2), E439-E449, 2022 | 24 | 2022 |
| Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation AJ Montano-Loza, V Ronca, M Ebadi, BE Hansen, G Hirschfield, S Elwir, ... Journal of hepatology 77 (1), 84-97, 2022 | 23 | 2022 |
| Healthy Alberta Communities: Impact of a three-year community-based obesity and chronic disease prevention intervention K Raine, R Plotnikoff, D Schopflocher, E Lytvyak, CI Nykiforuk, K Storey, ... Obesity Research & Clinical Practice 7 (2), e106, 2013 | 23 | 2013 |
| Impact on follow‐up strategies in patients with primary sclerosing cholangitis A Bergquist, TJ Weismüller, C Levy, C Rupp, D Joshi, JS Nayagam, ... Liver international 43 (1), 127-138, 2023 | 21 | 2023 |
| Impact of a 3-year multi-centre community-based intervention on risk factors for chronic disease and obesity among free-living adults: the Healthy Alberta Communities study E Lytvyak, DL Olstad, DP Schopflocher, RC Plotnikoff, KE Storey, ... BMC Public Health 16, 1-15, 2016 | 18 | 2016 |
| SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis C Efe, K Taşçılar, A Gerussi, F Bolis, C Lammert, B Ebik, AF Stättermayer, ... Journal of Autoimmunity 132, 102906, 2022 | 14 | 2022 |
| Management of inflammatory bowel disease patients with clinical care pathways reduces emergency department utilization E Lytvyak, RT Sutton, LA Dieleman, F Peerani, RN Fedorak, KI Kroeker Crohn's & Colitis 360 2 (4), otaa080, 2020 | 14 | 2020 |
| Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis E Lytvyak, I Hosamani, AJ Montano-Loza, L Saxinger, AL Mason | 14 | 2020 |
| Measuring the progress of capacity building in the Alberta Policy Coalition for Cancer Prevention KD Raine, C Sosa Hernandez, CIJ Nykiforuk, S Reed, G Montemurro, ... Health Promotion Practice 15 (4), 496-505, 2014 | 12 | 2014 |
Andrew Lawrence MasonUniversity of AlbertaVerified email at ualberta.ca
